Dicerna Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration acceptance of the Investigational New Drug application filed by Eli Lilly and Company for LY3819469, the second clinical-stage candidate to emerge from Dicerna's collaboration with Lilly. The IND milestone triggers a $10 million payment to Dicerna and enables Lilly to initiate a Phase 1 clinical trial of LY3819469, an investigational GalXC RNAi candidate targeting the LPA gene as a potential treatment of cardiometabolic diseases. The IND filing for LY3819469 is the second development milestone achieved under a 2018 global licensing and research collaboration between Dicerna and Lilly focused on the discovery, development and commercialization of potential new therapies for cardiometabolic and neurodegenerative diseases and pain. This investigational cardiometabolic therapy and future therapies to emerge from the two companies™ collaboration leverage Dicerna's proprietary GalXC RNAi technology platform. Under the agreement, Dicerna is eligible to receive up to $350 million in development and commercialization milestones for each GalXC hepatocyte target and $355 million for each non-hepatocyte target, as well as tiered royalties ranging from the mid-single-digits to low double-digits on potential product sales.